Brief: Aptose Provides Update On Apto-253 Program
20/12/2021 14:34
Dec 20 (Reuters) - Aptose Biosciences Inc APS.TO :
* APTOSE PROVIDES UPDATE ON APTO-253 PROGRAM
* APTOSE BIOSCIENCES INC- CLINICAL DEVELOPMENT OF THE MYC
REPRESSOR APTO-253 WILL BE DISCONTINUED
* APTOSE BIOSCIENCES INC- WILL FOCUS ON ADVANCING KINOME
INHIBITOR
PIPELINE
Further company coverage: APS.TO
Recent news on Aptose Biosciences
See all newsBrief: Aptose Biosciences Says Closing Of Arrangement With Hanmi Pharmaceutical Further Delayed
Brief: Aptose Reports First Quarter 2026 Results
Brief: Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan Of Arrangement
Brief: Leading Independent Proxy Advisory Firm Iss Recommends Aptose Biosciences Shareholders Vote “For” Proposed Plan Of Arrangement With Hanmi Pharmaceutical
Brief: Aptose Biosciences Announces Amendment To Arrangement Agreement And Details Of Shareholders Meeting